Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226


Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling.

Ho JM, Beattie BK, Squire JA, Frank DA, Barber DL.

Blood. 1999 Jun 15;93(12):4354-64.


HTLV-I-infected T cells evade the antiproliferative action of IFN-beta.

Smith D, Buckle GJ, Hafler DA, Frank DA, Höllsberg P.

Virology. 1999 May 10;257(2):314-21.


Hematopoietic growth factors signal through the formation of reactive oxygen species.

Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R, Griffin JD.

Blood. 1999 May 1;93(9):2928-35.


Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling.

Frank DA, Mahajan S, Ritz J.

Nat Med. 1999 Apr;5(4):444-7.


Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions.

Kirkwood JM, Farkas DL, Chakraborty A, Dyer KF, Tweardy DJ, Abernethy JL, Edington HD, Donnelly SS, Becker D.

Mol Med. 1999 Jan;5(1):11-20.


TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor.

Tomasson MH, Williams IR, Hasserjian R, Udomsakdi C, McGrath SM, Schwaller J, Druker B, Gilliland DG.

Blood. 1999 Mar 1;93(5):1707-14.


Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R.

Immunity. 1999 Jan;10(1):105-15.


In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.

le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C.

J Natl Cancer Inst. 1999 Jan 20;91(2):163-8.


IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells.

Wang KS, Ritz J, Frank DA.

J Immunol. 1999 Jan 1;162(1):299-304.


The Lck binding domain of herpesvirus saimiri tip-484 constitutively activates Lck and STAT3 in T cells.

Lund TC, Prator PC, Medveczky MM, Medveczky PG.

J Virol. 1999 Feb;73(2):1689-94.


Direct suppression of Stat1 function during adenoviral infection.

Look DC, Roswit WT, Frick AG, Gris-Alevy Y, Dickhaus DM, Walter MJ, Holtzman MJ.

Immunity. 1998 Dec;9(6):871-80.


Activation of the JAK-STAT pathway by reactive oxygen species.

Simon AR, Rai U, Fanburg BL, Cochran BH.

Am J Physiol. 1998 Dec;275(6 Pt 1):C1640-52.


4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.

Buchdunger E, Mett H, Trinks U, Regenass U, Müller M, Meyer T, Beilstein P, Wirz B, Schneider P, Traxler P, et al.

Clin Cancer Res. 1995 Aug;1(8):813-21.


STAT3 activation accompanies keratinocyte differentiation.

Hauser PJ, Agrawal D, Hackney J, Pledger WJ.

Cell Growth Differ. 1998 Oct;9(10):847-55.


Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation.

Danial NN, Losman JA, Lu T, Yip N, Krishnan K, Krolewski J, Goff SP, Wang JY, Rothman PB.

Mol Cell Biol. 1998 Nov;18(11):6795-804.


Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro.

Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ.

J Clin Invest. 1998 Oct 1;102(7):1385-92.


Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.

Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, Peeters P, Van Rompaey L, Van Etten RA, Ilaria R Jr, Marynen P, Gilliland DG.

EMBO J. 1998 Sep 15;17(18):5321-33.

Supplemental Content

Support Center